Curated news and analysis on clinical trials, drug approvals, and medical research.
AstraZeneca announced a $15 billion investment in Chinese R&D facilities through 2030, elevating China to a global innovation hub, while former China chief Leon Wang faces charges for unlawful data collection, illegal trade, and medical insurance fraud.
Can-Fite BioPharma's drug candidate namodenoson met its primary endpoint in a Phase 2a pancreatic cancer trial and demonstrated anti-obesity effects in a peer-reviewed preclinical study published in the International Journal of Obesity.
Moderna has settled with Arbutus and Genevant, facing a potential $1.3 billion liability contingent on Federal Circuit's decision. Multiple institutional investors have increased their stakes in the biotech company during recent quarters.
Novo Nordisk filed a patent infringement lawsuit against Hims & Hers over compounded versions of Wegovy. The legal action follows the telehealth company's announcement of a $49 oral pill, which was withdrawn after FDA warnings.
Citius Pharmaceuticals reported $3.9 million in first revenue from LYMPHIR's December 2025 launch for cutaneous T-cell lymphoma, while subsidiary Citius Oncology announced positive Phase 1 data showing 86% response rate when LYMPHIR was administered prior to CAR-T therapy in high-risk lymphoma patients.
Ocugen will host a conference call on March 4, 2026 at 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results and provide a business update, with a pre-market earnings announcement the same day.
A systematic review and meta-analysis demonstrates that semaglutide significantly reduces major adverse cardiovascular events in adults with type 2 diabetes, with particular benefits for nonfatal myocardial infarction and stroke.
The US military launched operations with Ecuador targeting designated terrorist organizations and struck three alleged drug boats in the Pacific and Caribbean, killing 11 people, as part of Operation Southern Spear.
Recent studies demonstrate brain stimulation therapies can accelerate depression treatment to five days and low-dose lithium may slow cognitive decline in seniors with mild cognitive impairment.
Ocular Therapeutix's Axpaxli outperformed low-dose Eylea in a Phase 3 trial for wet AMD, while Oculis Holding reported narrowed Q4 losses and expects Phase 3 trial readouts for OCS-01 in Q2 2026.
Roche signed an agreement to invest $478 million in Korea clinical trials over five years, marking the largest foreign pharmaceutical investment. Korean companies are also securing pre-approval licensing deals globally, demonstrating growing competitiveness.
A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.
The immuno-oncology market is projected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, driven by checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, with North America commanding 43% market share.
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
Researchers at the University of Bath have developed a bacterial system that produces, chemically stabilizes, and tests millions of peptide drug candidates inside living cells, identifying inhibitors of transcription factor CREB1 overactive in multiple cancers.
The global mRNA and next-generation vaccine platforms market is expected to grow from $39.69 billion in 2025 to $82.61 billion by 2030 at a 15.8% CAGR, driven by personalized medicine demand and infectious disease applications, while safety concerns and regulatory scrutiny continue.
The 2026 ASCO GU Symposium featured significant trial results in renal cell carcinoma, urothelial carcinoma, and prostate cancer, including data from LITESPARK-022, KEYNOTE-B15, SunRISE-2, and PEACE-3 studies.
U.S. Immigration and Customs Enforcement announced arrests of criminal illegal aliens convicted of sex crimes against children, drug trafficking, and gang activity. Nearly 70% of ICE arrests involve individuals charged or convicted of crimes in the U.S.
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
New research demonstrates blood-based biomarkers can predict testicular cancer recurrence and treatment outcomes, while separate study reveals long-term health risks vary by chemotherapy regimen in survivors.
